GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Targeting the RNA Exosome for Cancer Therapeutics

$479,616
Mats Ljungman · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Measuring and Modulating Oxidative DNA Damage Surveillance Pathways

$479,612
Eric T. Kool · Stanford University · R01 · FY2019 · CA

Overcoming stromal barriers to therapeutics in pancreas cancer

$479,510
Sunil R Hingorani · Fred Hutchinson Cancer Research Center · R01 · FY2013 · CA

A CELL-BASED APPROACH TO EARLY PANCREATIC CANCER DETECTION

$479,488
Trustees Of The University Of Pennsylvania, The · · FY2015 · Department of Defense

Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer

$479,470
Mark R. Kelley · Indiana University Indianapolis · R01 · FY2025 · CA

Drug Mechanism of Action-based targeting of tumor subpopulations

$479,435
Andrea Califano · Columbia University Health Sciences · U54 · FY2023 · CA

Utilizing islet autoantibody signatures for precision medicine in type 2 diabetes

$479,389
Nisa M Maruthur · Johns Hopkins University · R01 · FY2021 · DK

Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy

$479,283
Andre Elias Nel · University Of California Los Angeles · R01 · FY2024 · CA

Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression

$479,144
Mark R. Kelley · Indiana University Indianapolis · R01 · FY2014 · CA

A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging

$478,857
Esther H Chang · Synergene Therapeutics, Inc. · R41 · FY2006 · CA

Causes & Consequences of Acid pH in Tumors

$478,810
Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2015 · CA

Causes & Consequences of Acid pH in Tumors

$478,810
Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2014 · CA

Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer

$478,754
Julia Davydova · University Of Minnesota · R01 · FY2024 · CA

Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer

$478,728
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2018 · CA

Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer

$478,728
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2017 · CA

Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies

$478,329
Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies

$478,329
Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Case Control Study of Pancreas Cancer in Shanghai, China

$478,305
Harvey A Risch · Yale University · R01 · FY2010 · CA

The role of wild-type KRAS in the context of tumor profession and metastasis

$478,277
Gloria Huei-Ting Su · Columbia University Health Sciences · R01 · FY2019 · CA

NF-kB Regulation of the Muscle Microenvironment in Cancer Cachexia

$478,114
Denis C Guttridge · Medical University Of South Carolina · R01 · FY2022 · AR

Developing new therapeutic strategies for distinct Ras-driven cancers

$478,002
Karen M Cichowski · Brigham And Women'S Hospital · R01 · FY2025 · CA

Metaplastic Tuft Cells in Pancreatic Cancer

$477,977
Howard C Crawford · University Of Michigan At Ann Arbor · R01 · FY2020 · CA

T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research

$477,934
Denis Wirtz · Johns Hopkins University · T32 · FY2023 · CA

Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer

$477,871
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2021 · CA

The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling

$477,871
Gloria Huei-Ting Su · Columbia University Health Sciences · R01 · FY2019 · CA